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Radiopharmaceuticals based on 90Y are widely used  in  the treat ment of ma lig nant deseases.
In or der to meet the re quire ments for their fu ture ap pli ca tion, a 90Sr/90Y gen er a tor was de vel -
oped and 90Y eluted from this lo cally pro duced  gen er a tor was used for the radiolabelling of
the DOTA-con ju gated somatostatin an a log [DOTA0,Tyr3] octreotate and the prep a ra tion of
[90Y-DOTA0,Tyr3] octreotate (90Y-DOTATATE) for pep tide receptore radionuclide ther apy.
90Sr/90Y gen er a tor was based on the elec tro chem i cal sep a ra tion of 90Y from 90Sr in a  two-cy -
cle elec trol y sis pro ce dure. Three elec trode cells were used to per form both elec trol y ses. In
both cy cles, work ing elec trodes were kept on con stant po ten tial. The pH of the so lu tion was
ad justed to 2.7 of the value be fore the elec trol y ses.
The radionuclidic pu rity of the 90Y so lu tion was ana lysed by ITLC and ex trac tion pa per chro -
ma tog ra phy. The la bel ling of pep tide (100 µg DOTATATE) with 90YCl3 was per formed at 95
°C for  30 min utes. Radiochemical pu rity was de ter mined by HPLC and chro mato graphic
sep a ra tion, us ing a solid SepPak C-18 col umn.
Re sults ob tained con firmed  the ef fi ciency of our elec tro chem i cal sep a ra tion tech nique and
qual ity con trol meth ods for 90Y. The achieved ef fi ciency of the 90Sr/90Y gen er a tor above 96%
of the the o ret i cal value rep re sents  a good ba sis for the fur ther de vel op ment of this gen er a tor.
The la bel ling of the DOTATATE with 90Y ex hib ited a high ef fi ciency, too: there was less than
1% of 90Y3+in the 90Y-DOTATATE.
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IN TRO DUC TION
Radionuclide ther apy has been known for a long
time. The po ten tials of in ter nal tar get ra dio ther apy
have also been ac knowl edged for more than sixty
years, but the use of some novel radionuclides and
radiopharmaceuticals in the treat ment of solid can cer
has  rap idly in creased over the past  years.
Radionuclides with short phys i cal half-lives,
in the range from a few hours to a few days, could be
use ful in  radionuclide ther apy. Re cently, Yt -
trium-90 (90Y) has at tracted  a lot of  at ten tion as a 
prom is ing ther a peu tic ra dio iso tope [1]. 90Y has well 
known fa vour able fea tures: a half-life (64.1 hour),
con sis tent with the rate of an ti body ac cu mu la tion in
tu mours and no ac com pa ny ing  gamma ray   ra di a -
tion in  its  de cay. Beta rays have an  in ter me di ate  en -
ergy of 0.9367 MeV(bmax
−  = 2.28 MeV) and a sta ble
daugh ter (90Zr). The ma jor ad van tage of the use of
90Y in solid tu mours is  the con sid er able path length 
of its b– par ti cles (r95 = 5.9 mm) in tis sues.
90Y could be gen er ated by b– de cay of 90Sr (T1/2 = 
= 28.8 years) with which it ex ists in a sec u lar ra dio ac -
tive equi lib rium. A scheme of the  break through is pre -
sented as
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Be cause of its long half-life, 90Sr could be used
for an in def i nite  time, but this is also a se ri ous  lim i ta -
tion for the de vel op ment of an ad e quate 90Sr/ 90Y gen -
er a tor sys tem, as the pro duc tion of long-lived wastes
re quires care ful han dling and stor age. This is the prob -
lem that the use of such gen er a tors poses be fore  nu -
clear med i cine de part ments. Since 90Sr is a highly
toxic radionuclide, it is es sen tial that 90Sr should be
han dled in a well-es tab lished, con trolled lab o ra tory,
by trained per son nel.
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For the sep a ra tion of 90Y from 90Sr, sev eral sep a -
ra tion tech niques have been re ported, such as: ad sorp -
tion, sol vent ex trac tion, pre cip i ta tion, elec tro chem i cal 
sep a ra tion, and ion ex change [2-11]. The sep a ra tion of 
90Y from 90Sr by ad sorp tion chro ma tog ra phy on the
col umn is not con ve nient be cause of the deg ra da tion
of the col umn ma trix. Other tech niques, like the  sep a -
ra tion of car rier-free Y-90 from Sr-90 by cat ion ex -
change [12] or ion ex change [13] sol vent ex trac tion,
chro mato graphic sep a ra tion by the Eichrom-treated
col umn [14], the ex trac tion pa per chro ma tog ra phy
(EPC) tech nique [15-17] or with liq uid mem branes
[18, 19], could be use ful for ob tain ing 90Y, but they
gave more or less spe cific ra dio ac tiv ity, lower
radionuclidic pu rity, as well as a higher quan tity of
long-lived wastes.
The elec tro chem i cal method was sug gested for
the sep a ra tion of pure 86Y from 86Sr and the pro duc tion 
of 86Y, an at trac tive ra dio iso tope for pos i tron emis sion
to mog ra phy (PET) [20-23]. Suc cess ful elec tro chem i -
cal sep a ra tions of 90Y from 90Sr were pre sented by
Venkatesh et al, as well as by Chukravarty et al, [14,
24].
The cost-ef fec tive avail abil ity of the 90Y from a 
gen er a tor sys tem makes it very at trac tive. As im por -
tant is the fact  that 90Y can  eas ily bond to  many che -
late mol e cules, which is the ba sis  of its use in
radionuclide ther apy. So, 90Y-la belled com pounds,
such as pep tides, an ti bod ies, microspheres, ci trate and
phos phates, were de vel oped as a new class of
radiotherapeutic agents. Some of these agents were
de vel oped at the Vin~a In sti tute [25-29].
The treat ment with radiolabelled somatostatin an -
a logues was in tro duced in the 1990s, as a prom is ing 
ther apy for pa tients with in op er a ble or met a static
gastroentero-pancreatric neuroendocrine tu mours
(GEP-NET) [30]. A  ma jor ity of GEPNET ex hibit 
abun dant lev els of the somatostatin re cep tor which can
be vi su al ized in pa tients by the use of the radiolabelled
somatostatin an a logue, 111In-diethylenetriamine
pentaacetic acid (DTPA)-octreotide [31]. There is  a lot
of data in lit er a ture for the la belled pep tide-based
radiopharmaceuticals based on var i ous  radionuclides:
such as, 99mTc, 111In, for im ag ing, or 90Y, 177Lu ther apy
[32-42].
90Y, as a b–-emit ting radionuclide with high ac tiv -
i ties, has proved to be a suit able ra dio iso tope for  la bel -
ling mod i fied somatostatin an a logues, [DOTA0,Tyr3]
octreotide (90Y-DOTATOC) and [DOTA0,Tyr3]
octreotate (90Y-DOTATATE). Thus, 90Y-DOTATOC
and 90Y-DOTATATE were the next gen er a tion of
radiolabelled com pounds of the  pep tide re cep tor
radionuclide ther apy (PRRT) ther apy to be   de vel oped
[43-45].
 Con sid er able in ter est con cern ing the use of 
ther a peu tic radiopharmaceuticals ex ists in Ser bia. On
the other hand, 90Y is an ex pen sive ra dio iso tope,  re -
quir ing im port on a large scale be cause of the de cay
loss, mak ing it   in con ve nient for ev ery day med i cal ap -
pli ca tion in the im pov er ished healthcare sys tem of
Ser bia. There fore, a 90Sr/90Y gen er a tor sys tem, based
on the elec tro chem i cal sep a ra tion tech nique and pro -
ce dures for de ter min ing the radiochemical and
radionuclide im pu rity, were de vel oped [46]. Its use in
the cen tral ized radiopharmacy at the  Vin~a In sti tute
was es tab lished.
EX PER I MEN TAL
Ma te ri als
Ra dio ac tive sources 90Sr as stron tium ni trate,
90Sr(NO3) in equi lib rium with 90Y in 1 M HNO3, with
a spe cific ac tiv ity of 2.70 GBq/mg Sr, ra dio ac tive con -
cen tra tion of 9.240 GBq/cm3, as well as car rier-free
90YCl3 in a 0.05 M HCl so lu tion, ra dio ac tive con cen -
tra tion 89.590 GBq/cm3,  were ob tained from the In sti -
tute of Atomic En ergy, Ra dio iso tope Cen tre, Polatom,
Po land.
[DOTA-Tyr3] octreotate (DOTATATE) in
lyophilised form was pro vided from the In sti tute of
Atomic En ergy, Ra dio iso tope Cen tre Polatom, Po land.
[DOTA-Tyr3] octreotate TFA-salt of a pu rity
>95 % was pro vided by  Pi Chem (Graz, Aus tria). All
other re agents and sol vents were sup plied from com -
mer cial sources.
The potentiostat unit, Potentiostat/Galvanostat/
ZRA, Se ries G 750, was com posed of  li censed soft ware
FC 350 (Gamry In stru ments Inc., Warminster, Penn.,
USA).
The equip ment for the elec tro chem i cal sep a ra -
tion was com pleted with an elec trol y sis cell made by
the Fac ulty of Tech nol ogy and Met al lurgy, Uni ver sity
of Bel grade. A three-elec trode  sys tem was  housed in
quartz cells fit ted with an acrylic cap. Two elec trodes,
an an ode and a cath ode, with a sur face of 2 cm2, were
high-pu rity plat i num plats elec trodes made by the In -
sti tute for Min ing and Met al lurgy, Bor, Ser bia. As a
ref er ence elec trode, sat u rated cal o mel elec trode
(SCE), (Gamry In stru ments, Inc.), in a ref er ent cell,
con nected by Lugin’s cap il lary with an  elec tro chem i -
cal cell, was used. High-pu rity ar gon gas was pro vided  
from a lo cal sup plier.
The ra dio ac tiv ity of 90Sr and 90Y was mea sured
in an ion is ation cham ber (Capintec CRC-15 Beta
Count ing Cal i bra tor, Ramsey, N. J., USA) which con -
tains a cal i bra tion fac tor. For cal i brat ing the 90Y dose
sec ond ary  cal i bra tion source of 90Sr, a  (ra dio ac tive
so lu tion am poule No BW/21/10/R3-0.1, with an  ac tiv -
ity of 368.3 ± 9.6 kBq/Lg, dated De cem ber 15th,
2010), was used. A low level of ac tiv ity was mea sured
in the NaI(Tl) scin til la tion coun ter (Wallace Comp.
Gamma Coun ter, LKB, Fin land) by mea sur ing the
Bremmstrahlung ra di a tions of 90Sr and 90Y.
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The HPLC anal y sis of the 90Y-DOTATATE was
per formed us ing the High Pres sure Liq uid
Chromatograph, Hewlett Packard 1050 S/N (Palo Alto,
Cal., USA), with an UV and gamma flow de tec tor
(Raytest Aus tria GmbH, Langenzersdorf, Aus tria), with
a RP C18 col umn (250 mm × 4.6 mm). Chro mato graphic 
sep a ra tion was done by SepPak C-18 col umn (Wa ters,
Milford, Mass., USA), ac ti vated by 95% C2H5OH.
Prep a ra tion of the 90Sr-90Y gen er a tor
90Sr-90Y elec tro chem i cal gen er a tor was based
on the elec trol y sis of a mix ture of 90Sr and 90Y in ni -
trate form. The elec trol y sis was per formed in a quartz
cell with a of vol ume 100 cm3 charged with 0.2 ml of
90Sr (NO3) in 1 M HNO3 (~1.85 GBq), while the elec -
tro lyte of the to tal vol ume of 50 ml amounted to  0.003
M HNO3. The pH value was ad justed prior to the elec -
trol y sis with 3% am mo nia to 2.7 ± 0.2. Be fore the elec -
trol y sis, ar gon was bub bled for 15 minutes, pass ing
through a glass tube which was dipped into the elec -
trol y sis so lu tion and plat i num elec trodes were ac ti -
vated in 3 M HNO3.
The three-elec trode sys tem was housed in quartz 
cells fit ted with an acrylic cap. The work ing and aux il -
iary elec trode,  sealed in a glass holder, were fully im -
mersed in  the so lu tion, fac ing each other. They were
main tained at a very low dis tance and the ref er ence
elec trode (SCE) was kept very close to the cath ode,
with out touch ing it.
Elec tro chem i cal sep a ra tion of 90Y
The elec trol y sis was per formed in a two-step
pro ce dure . Dur ing the first elec trol y sis, 90Y was sep a -
rated from 90Sr by se lec tive elec tro de pos it ing of 90Y
on the plat i num cath ode. This was achieved by ap ply -
ing a fixed po ten tial on the cath ode of –2.5 V with re -
spect to SCE. High-pu rity ar gon gas was con tin u ously
passed through the so lu tion to vent gases like H2, and
the so lu tion  con tin u ously mixed by a mag netic stir rer.
The first elec trol y sis lasted 90 minutes. At the end of
the se lec tive elec tro de pos it ing of 90Y, the elec trodes
with the acrylic cap were re moved from the quartz cell, 
with out switch ing off the power sup ply. Then the
power sup ply  was switched off, the cath ode plate  re -
moved from the acrylic cap and washed with 10 ml of
ac e tone. Af ter that, the cath ode was trans ferred to the
sec ond quartz cell.
Dur ing the sec ond elec trol y sis, the so cold “pu ri -
fi ca tion step”, 90Y was re moved from the plat i num
elec trode. In this step, the cath ode from the first elec -
trol y sis con tain ing 90Y was used as an an ode, but a
new plat i num elec trode was used as a cath ode. The
electrods were fully im mersed in  the so lu tion, in a
sim i lar new elec tro lytic cell filled with fresh 0.0003 M
NaNO3 and pH ad justed to 2.7 ± 0.2. This step of the
elec trol y sis took 45 minutes and was per formed as a
galvanostatic elec trol y sis, at a fixed po ten tial of –2.5
V on the cath ode with re spect to SCE. Ar gon was con -
tin u ously passed through the so lu tion. In this elec trol -
y sis, 90Y was trans ferred from the first plat i num elec -
trode to the fresh plat i num elec trode (cath ode) and
then  de pos ited on it. Af ter the elec tro de pos it ing of
90Y, the cath ode was taken out with out switch ing off
the cur rent and washed with 10 ml ac e tone and then 
dis solved by dip ping it in a small vol ume of 0.5 M
HCl, so as to ob tain 90YCl3 suit able for la bel ling.
In the ini tial  ex per i ments, 90Sr in equi lib rium with
90Y with rel a tively low ac tiv ity (~1.85 GBq) was used.
Qual ity con trol of 90Y
The radionuclidic pu rity of the 90Y so lu tion was
ana lysed by pa per and ITLC chro ma tog ra phy. Chro -
ma tog ra phy pa per Whatman N° 1 (18 cm × 2 cm) and
ITLC SG strips (14 cm × 1 cm)  of  nor mal sa line (0.9% 
NaCl) were used.
In or der to de ter mine the radionuclidic pu rity of the
90Y so lu tion, the so called  “BARC tech nique” was  used
[36, 37]. This method is  a com bi na tion of sol vent ex trac -
tion and pa per chro ma tog ra phy (ex trac tion pa per chro -
ma tog ra phy − EPC). Whatman N° 1 (18 cm × 2 cm) pa -
per chro ma tog ra phy strips im preg nated with 2-ethyl
hexyl, and  2-ethyl hexyl phosphonic acid (KSM-17) at
the point of spot ting were  used. Upon de vel op ment with
nor mal sa line, 90Sr moves to the sol vent front, leav ing
90Y com pletely chelated and re tained at the point of spot -
ting. The ac tiv ity at the sol vent front was es ti mated by
cut ting the chromatograms in 1 cm pieces  and by mea -
sur ing the  ra dio ac tiv ity in a NaI(Tl) scin til la tion coun ter. 
Radionuclidic pu rity was cal cu lated as a per cent age of
the to tal spot ted ac tiv ity. 
Prep a ra tion  and qual ity
con trol of 90Y-DOTATATE
Prep a ra tion  of DOTATATE and its
la bel ling with 90Y
The so lu tion of the DOTATATE was pre pared un der
asep tic con di tions, by dis solv ing the [DOTA-Tyr3]
octreotate in ascor bic acid so lu tion pH = 4.5. 0.5 ml
aliquots, dis pensed in glass vi als and freeze-dried for  24
hours. Thus,  sam ples with 100 µg DOTATATE and 50 mg
ascor bic acid were ob tained as lyophilised pow der in a vac -
uum.
The re con sti tu tion of the freeze-dried DOTATATE
was done in the same man ner  for both the DOTATATE
ob tained from Polatom, Po land, and the one pre pared at
the Vin~a In sti tute by add ing 0.5 ml aliquots of ster ile
nor mal sa line into the vi als with the DOTATATE  and
mix ing.
The DOTATATE de vel oped at the  Vin~a In sti -
tute was la belled by  add ing  37 MBq of 90YCl3 only
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for re search pur poses. The 90Y-la bel ling of the pep tide
was per formed at 95 °C, for 30 minutes. The heat ing
and shak ing was done in a tem per a ture-con trolled
heat ing bath. Af ter 30 minutes, the vial was cooled for
1-2 minutes in cold wa ter to  room tem per a ture and
ace tic acid (50 mg/ml, pH 4.5) as a sta bi lizer  added.
The fi nal vol ume was ad justed up to 3 ml. 
DOTATATE (Polatom) was la belled with
1.85-5.55 GBq of 90YCl3. The con tent of the  vial was
quan ti ta tively trans ferred to a vial with 90YCl3. The la -
bel ling pro ce dure was the same as for the sam ples pre -
pared in our Lab o ra tory. These sam ples of
90Y-DOTATATE (18.5-37.0 MBq/1 µg DOTATATE)
were pre pared for the treat ment of  pa tients.
The ste ril ity of the la belled com pound was ob -
tained by work ing un der asep tic con di tions and with
ster il ized equip ment with  ad di tional  fil tra tion by  0.22 
µm fil ters (Millipore).
Qual ity con trol of 90Y-DOTATATE
The radiochemical pu rity (RCP) of the 90Y-la -
belled DOTATATE was de ter mined by HPLC and
solid phase sep a ra tion us ing SepPak C-18 mini col -
umns (car tridges). 
HPLC
A sam ple of the 90Y-DOTATATE was ob tained
by dis solv ing 90Y-DOTATATE (5 µl) in a mix ture of
500 µl 0.4 M so dium ac e tate (pH 4.5) and 1 mg/ml
diethylen triamino pentaacetic acid (DTPA). The
HPLC anal y ses of the 90Y-DOTATATE sam ple was
per formed by use of two sol vents: 0.1% trifluoroacetic 
acid (TFA) in wa ter (sol vent A) and acetonitrile (sol -
vent B), by the gra di ent elu tion tech nique: 0-5 minutes 
95% B; 5-10 minutes: from 95%-0% B; 10-15 minutes 
0% B; from 15-20 minutes: from 0% to 95% B; 20-25
minutes: 85% B. The flow rate was 0.7 ml/minutes.
UV was de tected at 254 nm and ra dio ac tiv ity by  ra dio -
met ric de tec tion. 
Solid phase SepPak sep a ra tion
A SepPak C-18 mini col umn was ac ti vated with
5 ml of 95% eth a nol (C2H5OH) and then washed with
10-15 ml of nor mal sa line (0.9% NaCl). A sam ple of
the 90Y-DOTATATE (10-20 µl) dis solved in 500 µl of
nor mal sa line was loaded onto the col umn and then
washed out with 5 ml of nor mal sa line (frac tion A with
90Y3+). This step was fol lowed by the wash ing out of
the col umn with 5 ml of 95% C2H5OH (frac tion B with 
90Y-DOTATATE). 
RCP was cal cu lated as the per cent age of frac tion
B ac tiv ity, ac cord ing to the equa tion
B B
B A
[%] =
+
(2)
RE SULTS AND DIS CUS SION
Elec tro chem i cal sep a ra tion of
90Y and its qual ity con trol 
90Sr/90Y gen er a tor was based on the elec tro -
chem i cal sep a ra tion of 90Y, ac cord ing to the  method of 
Chacravatry et al. [24]. In this gen er a tor, the dif fer -
ence be tween the elec tro chem i cal po ten tials of Y3+
and Sr2+  was  ex plored so as to achieve a clean and
quick sep a ra tion of 90Y from the par ent radionuclide,
90Sr. The elec trol y sis was car ried out in an elec trol y sis
quartz cell,” as apotentiostatical elec trol y sis with a po -
ten tial of − 2.500 V ± 0.055 with re spect to SCE. Dur -
ing the first elec trol y sis, the cur rent was in creased
from 730 mA to 745 mA as the elec trol y sis neared  the
end. The elec tro lytic po ten tial at the plat i num cath ode
was sta ble dur ing the elec trol y sis, but could not be
main tained at − 2.50 V over the du ra tion of  the elec -
trol y sis. It fell  to − 2.39 V,  still within the al lowed
limit of <(±0.2)% plus 5 mV, in a con stant volt age
mode for an used potentiostatic unit. The pH was ad -
justed at 2.7 ± 0.2. 
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Fig ure 1. Equip ment for elec tro chem i cal sep a ra tion,
Lab o ra tory for Ra dio iso topes, Vin~a In sti tute (a); with
elec tro chem i cal cell (b)
The sec ond elec trol y sis was ac com plished at a
sta ble po ten tial at the plat i num cath ode − 2.50 V dur -
ing the elec trol y sis, at a con stant cur rent of 100 mA.
The warm ing  of the so lu tion dur ing the elec trol y sis
was re mark able, so that the cool ing of the elec trol y sis
cell was nec es sary. A  sep a ra tion of the  H2 gas was
also de tected, there fore the stir ring dur ing the pro cess
seems to be un nec es sary. These con di tions had to en -
sure the de po si tion yield above 90%. There was a need 
to con vert 90Y into a  form  ap pli ca ble to   med i cine
ther apy.
90Y ex ists in sec u lar equi lib rium with its par ent
iso tope stron tium-90 (90Sc) a prod uct of fis sion re ac -
tion. There were many im pu ri ties which had to  be re -
moved, in clud ing pure 90Y. Ra dio ac tive 90Sr as
90Sr(NO3)2 in equi lib rium with 90Y in 1 M HNO3, ob -
tained from Polatom, Po land, was of high
radionuclidic pu rity (>99.5%), as well as of high
radiochemical pu rity, so we ex pected 90Y ob tained by
the elec tro chem i cal sep a ra tion method from the
90Sr/90Y gen er a tor to be of high radiochemical pu rity.
90Sr break through is  a  ma jor prob lem of ten en -
coun tered with the 90Sr/90Y gen er a tor. Be cause 90Sr is
a bone seeker, the up per limit of 90Sr in the 90Y so lu tion 
for hu man use is 74 kBq (2 mCi) [24]. In or der to pro -
vide data con cern ing 90Sr con tam i na tion, the de vel op -
ment of  meth ods for the de ter mi na tion of chem i cal
and radionuclide im pu rity was nec es sary.
The qual ity of the said sep a ra tion was in ves ti -
gated by mea sur ing the ra dio ac tiv ity of the 90Y-so lu -
tion over  the course of time, fol low ing the half-life of
90Y. The de crease was fol lowed for 31 days i. e, a ~11.6 
half-life of 90Y. The ab sence of de vi a tion in the lower
part of the curve in fig. 2 con firmed the ab sence of
90Sr. In the  fig ure pre sented, the y-axis was given as
the log a rithm of ob tained val ues.
The radionuclidic pu rity of the 90Y so lu tion was
ana lysed by pa per and ITLC chro ma tog ra phy. Chro ma -
tog ra phy pa per Whatman N° 1 (18 cm × 2 cm) and
ITLC SG strips (14 cm × 1 cm) and 0.9% sa line so lu tion 
were  used for the anal y ses. Dur ing the chro ma tog ra -
phy, 90Sr moved with the sol vent front, while 90Y stayed 
at the or i gin. As the mix ture of 90Sr and 90Y was at low
ac tiv ity, at the megabecquerel level, the ac tiv ity at the
sol vent front was es ti mated by use of dose cal i bra tor
(Capintec CRC 15R, USA) which con tains a cal i bra tion 
fac tor and then com pared with the to tal spot ted ac tiv ity.
In ad di tion, the ac tiv ity of the so lu tion was tested and
mea sured for a month. Com par a tive re sults of the
radiochemical pu rity of 90Y be fore and af ter elec trol y -
sis, ob tained by pa per chro ma tog ra phy, were given in
fig. 3(a) and fig. 3(b). The so lu tion of stron tium and yt -
trium was in a bal ance, and its lay out  shown in fig. 3(a) 
where two peaks were vis i ble. The ab sence of a peak at
10 cm  rep re sent ing  stron tium fig. 3(b) in di cates that
the sep a ra tion of yt trium from stron tium by elec tro -
chem i cal sep a ra tion was suc cess ful.
In or der to de ter mine the radionuclidic pu rity of
the 90Y so lu tion, a com bi na tion of sol vent ex trac tion
and pa per chro ma tog ra phy (ex trac tion pa per chro ma -
tog ra phy EPC − “BARC tech nique”) was also used in
our ex per i ments. This method was sug gested as a sen -
si tive and ac cu rate an a lyt i cal tech nique for the es ti ma -
tion of the pu rity of 90Y [13]. The EPC pat tern of 90Y
ob tained upon de vel op ment with nor mal sa line was
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Fig ure 2. Ra dio ac tive de cay pat tern of 90Y pre pared by
the elec tro chem i cal sep a ra tion method (>11 half lives)
Fig ure 3. (a) Stron tium/Yt trium in equi lib rium,
and (b) Yt trium af ter elec trol y ses
pre sented in fig. 4. 90Sr moved to the sol vent
frontleaving 90Y com pletely chelated and re tained at
the point of spot ting.  Radionuclidic pu rity was cal cu -
lated as a per cent age of the to tal spot ted ac tiv ity, es ti -
mated by mea sur ing  ra dio ac tiv ity in a dose cal i bra tor.
These re sults have shown that a very low level of 90Sr,
not more than 0.2%, was found for 5 re peated elec trol -
y sis pro ce dures.
Prep a ra tion  and qual ity
con trol of 90Y-DOTATATE
Fifty-nine labellings of the com mer cially avail -
able DOTATATE with 90YCL3 (Polatom, Po land) done
over  the last five years were ob served. Radiochemical
pu rity re sults of the 90Y-DOTATATE (RCP) ob tained 
by solid phase SepPak sep a ra tion have shown that in the  
fifty-three la belled batches pre pared and la belled ac -
cord ing to pro ce dure, only 49.0% of the batches were
on RCP over 99.0%, 73.6% had RCP higher than 98%,
84.9% had RCP higher than 95.0%, while  15.1% of all
pre pared batches had more than 10% of Y3+.
A  part of the RCP re sults, along  with the con tent
of chem i cal im pu ri ties of 90Y in µg/ml (Cu, Ni, As, Pb,
Fe, Zn), were pre sented in tab. 1. Be cause of the in suf -
fi cient  qual ity con trol of the re sults for all of the used
batches of 90Y, RCP re sults for only 33 la belled sam -
ples were pre sented. As can  be seen from tab. 1, the
con tent of  met als ana lysed by the ICP OES spec trom -
e try method on the  day  of  their  pro duc tion was
within the lim its de clared by the man u fac turer (Cu, Ni, 
As < µg/ml, Pb < 5.0 µg/ml, Fe, Zn (<10.0 µg/ml). As
we have used 90YCl3 four days af ter the date of pro -
duc tion and qual ity con trol, the con tent of the el e ment
could in crease. Qual ity con trol re sults for
90Y-DOTATATE were in ac cor dance with the con tent
of listed met als in yt trium chlo ride: the higher the con -
tent of met als, es pe cially Pb, Fe, and Zn, the higher the
per cent age of free Y3+ in DOTATATE sam ples la -
belled with 90YCl3. As more than 15% of the pre pared
batches con tained  over  10% of Y3+, it was ob vi ous
that the in flu ence  of the listed met als was high.
For pa tient ap pli ca tion, we have used the batches
on RCP over 98%, with out any pu ri fi ca tion. For these
sam ples of the 90Y-DOTATATE, there was (0.79 ±
±.0.58)% of 90Y3+in the 90Y-DOTATATE (mean ± stan -
dard de vi a tion SD), de ter mined by solid phase SepPak
sep a ra tion.
In the same way, the qual ity con trol of the batches
of DOTATATE de vel oped in  our Lab o ra tory and la -
belled with 90Y by the  90Sr/90Y gen er a tor (Vin~a In sti -
tute), was done 15 min utes af ter the prep a ra tion  and re -
peated af ter 24 hours. The re sults of the HPLC anal y ses
were pre sented in  fig. 5. Radiochromatograms have
shown that  the pre pared sam ples of the 90Y-DOTATATE
(Rf = 12.532 − 12.822) were of  high radiochemical pu -
rity, higher than 99% 15 min utes af ter prep a ra tion and
higher than 96%, 24 hours af ter prep a ra tion, again with -
out a  sta bi liser, con firm ing the  sta bil ity of the la belled
com pound.
CON CLU SIONS
First re sults of the use of the 90Sr/90Y gen er a tor
have con firmed the fea si bil ity of   a prac ti cal ap pli ca -
tion of the elec tro chem i cal sep a ra tion pro ce dure. This
seems  a su pe rior and low-cost tech nique for a per ma -
nent sup ply of 90Y suit able for ther a peu tic ap pli ca tion. 
90Sr in equi lib rium with 90Y with a rel a tively low 
ac tiv ity (~1.85 GBq) was used for these ex per i ments.
The ef fi ciency of the 90Sr/90Y gen er a tor was above
96% of the the o ret i cal value and rep re sents a good ba -
sis for fur ther de vel op ment of the 90Sr/90Y gen er a tor.
These re sults were also a con fir ma tion that we have
suc cess fully com pleted the equip ment  of the 90Sr/90Y
elec tro chem i cal gen er a tor and es tab lished a vi a ble
elec tro chem i cal sep a ra tion tech nique.
A  pro ce dure for pre par ing the DOTATATE and
its la bel ling with 90Y was de vel oped, too. The first la -
bel ling re sults of DOTATATE with home-made 90Y
have shown  high radiochemical pu rity, pos si bly con -
firm ing the good qual ity of 90Y ob tained from the
90Sr/90Y gen er a tor.
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Fig ure 4. Ex trac tion pa per chro ma tog ra phy re sults
(EPC) of 90Y from the 90Sr/90Y elec tro chem i cal gen er a tor
Fig ure 5. HPLC radiochromatograms for 90Y-DOTATATE
(Vin~a In sti tute); (a) 15 min utes and (b) 24 hours af ter
radiolabelling
Our fu ture plans in volve   the set ting up of ad e -
quate fa cil i ties for han dling  higher ac tiv i ties  and for
stan dard iz ing   pro ce dures for the pro duc tion and qual -
ity con trol of 90Y. Our  next step will be the  es tab lish -
ment of pro to cols for the use of 90Y in the  la bel ling of
the DOTATATE and  other lig ands, as well as the task of
pro vid ing  the  nu clear med i cine  com mu nity of Ser bia
with ef fi cient radiopharmaceuticals for radionuclide
ther apy  in the treat ment of can cer dis eases.
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ELEKTROHEMIJSKA  SEPARACIJA  ITRIJUMA-90  U
ELEKTROHEMIJSKOM 90Sr/90Y  GENERATORU I  WEGOVO
KORI[]EWE  ZA RADIOOBELE@AVAWE  DOTA-KOWUGOVANOG 
SOMATOSTATINSKOG  ANALOGA  [DOTA0, Tyr3] OCTREOTATE
Radiofarmaceutici bazirani na 90Y se sve vi{e koriste u tretmanu malignih oboqewa.
Da bi se izi{lo u susret budu}im potrebama, razvijen je 90Sr/90Y gen er a tor. Dobiveni 90Y eluat je
kori{}en za radioobele`avawe analoga kowugovanog DOTA somatostatina [DOTA0, Tyr3]
octreotate i pripremawe [90Y-DOTA0, Tyr3] octreotate (90Y-DOTATATE), peptidnim receptorima u
radionuklidnoj terapiji. 90Sr/90Y gen er a tor je baziran na elektrohemijskom odvajawu 90Y od 90Sr u
dvostepenoj elektrolizi. Sistem sa tri elektrode je kori{}en za obe elektrolize. U svakoj
elektrolizi potencijal radne elektrode je odr`avan konstantnim, dok je pH vrednost rastvora
bila pode{ena na 2,7. 
Radionuklidna ~isto}a rastvora 90Y je analizirana pomo}u in stant tankoslojne i papirne
hromatografije. Peptid (100 µg DOTATATE) je obele`avan 30 minuta na 95 °C. Radiohemijska
~isto}a je odre|ena pomo}u HPLC i hromatografskim razdvajawem koriste}i ~vrstu SepPak C-18
kolonu. 
Dobiveni rezultati potvr|uju efikasnost kako elektrohemijskog odvajawa, tako i
metodu za kontrolu kvaliteta 90Y. Postignuta efikasnost 90Sr/90Y generatora od 96% teorijske
vrednosti je dobra osnova za budu}i razvoj ovog generatora. Obele`avawe DOTATATE sa 90Y je
tako|e bilo visoko efikasno jer je bilo mawe od 1% slobodnog Y3+ u rastvoru nakon obele`avawa
90Y-DOTATATE.
Kqu~ne re~i: radionuklidna terapija, 90Y, 90Sr/90Y  gen er a tor, radioobele`avawe,  
..........................90Y-DOTATATE
